Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

mRNA-based MRI contrast agent for precise diagnosis of glioma and pseudoprogression.

Cell biomaterials·2026
Same author

A modular hydrogel system with independent control of bioadhesion, fibrosis, and stiffness.

Science advances·2026
Same author

Engineering drug-responsive replication machinery for precise control of self-amplifying RNA.

Nature biomedical engineering·2026
Same author

Programmable mRNA 3'UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer.

Nature biomedical engineering·2026
Same author

The Use of Deep Learning in RNA Therapeutic Development.

ACS nano·2026
Same author

Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine.

Science advances·2026

Related Experiment Video

Updated: Oct 24, 2025

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
10:02

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

2.4K

Lipid nanoparticles for mRNA delivery.

Xucheng Hou1, Tal Zaks2, Robert Langer3,4

  • 1Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH USA.

Nature Reviews. Materials
|August 16, 2021
PubMed
Summary
This summary is machine-generated.

Lipid nanoparticles are crucial for delivering messenger RNA (mRNA) therapeutics. This review covers their design, clinical translation, and applications in treating diseases like COVID-19.

Keywords:
Drug deliveryDrug development

More Related Videos

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

10.3K
Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
08:55

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

12.6K

Related Experiment Videos

Last Updated: Oct 24, 2025

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
10:02

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

2.4K
Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

10.3K
Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
08:55

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

12.6K

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Molecular Therapeutics

Background:

  • Messenger RNA (mRNA) therapeutics offer a novel approach for disease prevention and treatment.
  • Effective in vivo delivery of mRNA necessitates systems that ensure stability, cellular uptake, and release.
  • Lipid nanoparticles (LNPs) have emerged as a successful delivery platform, notably in mRNA vaccines for COVID-19.

Purpose of the Study:

  • To review the design principles of lipid nanoparticles for mRNA delivery.
  • To examine physiological barriers and administration routes for LNP-mRNA systems.
  • To discuss key considerations for the clinical translation of LNP-mRNA formulations.

Main Methods:

  • Literature review of LNP design for mRNA delivery.
  • Analysis of physiological barriers and administration routes.
  • Evaluation of clinical translation factors including manufacturing, stability, storage, and safety.
  • Highlighting preclinical and clinical studies across various therapeutic areas.

Main Results:

  • Lipid nanoparticles are a clinically validated platform for mRNA delivery.
  • Successful application of LNP-mRNA vaccines against COVID-19 demonstrates platform potential.
  • Ongoing research explores LNP-mRNA therapeutics for infectious diseases, cancer, and genetic disorders.

Conclusions:

  • Lipid nanoparticles represent a significant advancement in mRNA therapeutics.
  • Further research and development are needed to overcome remaining challenges for broader clinical application.
  • The technology holds promise for future therapeutic innovations across diverse medical fields.